TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05353816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corheart 6 Left Ventricular Assist System
Description: Implantation of the Corheart 6 Left Ventricular Assist Device for mechanical circulatory support.
Study: NCT05451849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TC-510
Description: TC-510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study: NCT06422299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online, couples-based intervention
Description: During Phase 1 of the present study, the intervention will be iteratively developed using a rigorous, user-centered design approach through integration of knowledge gained from Phase 1 dyadic analyses and qualitative interviews, and existing gold-standard treatments for substance use among couples, including Integrative Behavioral Couples Therapy (IBCT; Christensen \& Doss, 2016) and Behavioral Couples Therapy for Alcohol (ABCT; McCrady et al, 1995) and substance use brief interventions for young adults (Halladay, et al., 2019; Tanner-Smith et al., 2015).
Study: NCT04950673

Intervention type: DEVICE
Intervention: Cognivue
Description: Computerized Cognitive Assessment Device

Intervention type: DEVICE
Intervention: Cognivue
Description: Computerized Cognitive Assessment Device
Study: NCT04836637

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium-carbonate
Description: Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium-enriched permeate
Description: Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium-enriched permeate with Inulin
Description: Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
Study: NCT05270629

Intervention type: OTHER
Intervention: Antegrade and retrograde anastomoses
Description: Patients who had received both antegrade and retrograde anastomoses.

Intervention type: OTHER
Intervention: Antegrade-only anastomoses
Description: Patients who had received antegrade-only anastomoses.
Study: NCT04785027

Intervention type: DRUG
Group type: OTHER
Intervention: PSORI-CM01 formula
Description: PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
Study: NCT05844696

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.
Description: 〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.
Description: 〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation.
Study: NCT05581277

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-individual format.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-individual format.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-individual format.
Study: NCT05844696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.
Description: 〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation.
Study: NCT06374433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occipital tACS at IAF-2Hz
Description: tACS applied to occipital areas at 2 Hz below the individual alpha frequency (IAF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occipital tACS at IAF+2Hz
Description: tACS applied to occipital areas at 2 Hz above the individual alpha frequency (IAF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frontal tACS at 4-7 Hz
Description: tACS applied to frontal areas at 4-7 Hz

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occipital tRNS
Description: tRNS applied to occipital brain regions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frontal tRNS
Description: tRNS applied to frontal brain regions

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham/placebo tACS
Description: tACS is activated only for 30 seconds and then turned off, thus resulting ineffective

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham/placebo tRNS
Description: tRNS is activated only for 30 seconds and then turned off, thus resulting ineffective
Study: NCT05929222

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Involved-Site Radiation Therapy 24Gy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Obinutuzumab
Description: Involved-Site Radiation Therapy 24Gy followed by Obinutuzumab 1000mg flat dose 4 doses weekly plus addition 4 doses every 3 weeks
Study: NCT06088082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
Study: NCT06665464

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil supplement 1
Description: Soft gel capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplement 2
Description: Soft gel chewable
Study: NCT06242184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A(Nano-fortified Adhesive)
Description: Nano-fortified dentin adhesive

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B(Adhesive without nanoparticles)
Description: Conventional adhesives without nanoparticles
Study: NCT05195034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
Study: NCT04785027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gu Ben Hua Yu formula
Description: Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
Study: NCT05195034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Study: NCT06669533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
Study: NCT04785027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose-derived multipotent mesenchymal stem cells
Description: AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: adipose-derived multipotent mesenchymal stem cells
Description: AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
Study: NCT06062758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECT Simulation Training
Description: Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
Study: NCT05683600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
Description: Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
Study: NCT04766879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfluthrin
Description: Passive emanator with formulated transfluthrin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Passive emanator with formulated inert ingredients
Study: NCT05004259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: Subcutaneous injection of daratumumab and hyaluronidase
Study: NCT06573411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI/ARB+ finerenone
Description: The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACEI/ARB+ Placebo
Description: Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
Study: NCT06408285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3927 powder for inhalation
Description: TQC3927 is a targeted inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC3927 powder for inhalation placebo
Description: TQC3927 powder for inhalation placebo contains no active substance.
Study: NCT06477796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning Bright Light Therapy
Description: Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Negative Ion Generator
Description: Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
Study: NCT06417749

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control arm
Description: Participants will receive a copy of the Chinese Dietary Guidelines leaflet at baseline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention arm
Description: Participants will be given three MIND diet education videos on different topics at baseline and during follow-up. In addition, each participant will receive a MIND diet education brochure at baseline and some food supply during follow-up.
Study: NCT04936009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
Study: NCT06669533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
Study: NCT06517706

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of tDCS (device) with cognitive training (behavioral)
Description: Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive two sessions of tDCS plus cognitive training with the Categorization Program

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Categorization Program
Description: Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive cognitive training and sham tDCS
Study: NCT05988385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive airway pressure
Description: Positive airway pressure (PAP) therapy is a sleep apnea treatment that uses a stream of compressed air to support the airway during sleep. With PAP therapy, a mask is worn during sleep and a portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing.

Intervention type: DEVICE
Group type: OTHER
Intervention: Positive airway pressure
Description: Positive airway pressure (PAP) therapy is a sleep apnea treatment that uses a stream of compressed air to support the airway during sleep. With PAP therapy, a mask is worn during sleep and a portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral appliance therapy
Description: Oral appliance therapy involves the use of a dental appliance or oral mandibular advancement device that prevents the tongue from blocking the throat and/or advances the lower jaw forward. These devices help keep the airway open during sleep.

Intervention type: DEVICE
Group type: OTHER
Intervention: Oral appliance therapy
Description: Oral appliance therapy involves the use of a dental appliance or oral mandibular advancement device that prevents the tongue from blocking the throat and/or advances the lower jaw forward. These devices help keep the airway open during sleep.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positional therapy
Description: A NightShift Sleep Positioner (Advanced Brain Monitoring) is a neck vibration device, FDA approved to treat positional sleep apnea. The device detects patient supine position and delivers a small vibratory signal to the back of the neck to prompt position change.

Intervention type: DEVICE
Group type: OTHER
Intervention: Positional therapy
Description: A NightShift Sleep Positioner (Advanced Brain Monitoring) is a neck vibration device, FDA approved to treat positional sleep apnea. The device detects patient supine position and delivers a small vibratory signal to the back of the neck to prompt position change.
Study: NCT06616415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT06602362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partnered sex involving choking
Description: When a subject submits a survey indicating that they engaged in partnered sex involving choking, they will be asked to come in for data collection within 24 hours of survey submission.
Study: NCT04711304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-derived Wharton's Jelly
Description: Intraarticular injection
Study: NCT06602362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partnered sex involving choking
Description: When a subject submits a survey indicating that they engaged in partnered sex involving choking, they will be asked to come in for data collection within 24 hours of survey submission.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partnered sex not involving choking
Description: When a subject submits a survey indicating that they engaged in partnered sex that did not involve any choking, they will be asked to come in for data collection within 24 hours of survey submission.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partnered sex not involving choking
Description: When a subject submits a survey indicating that they engaged in partnered sex that did not involve any choking, they will be asked to come in for data collection within 24 hours of survey submission.
Study: NCT05942183

Intervention type: DIAGNOSTIC_TEST
Intervention: ONSD
Description: ultrasound measurement of the optic nerve sheath diameter

Intervention type: DIAGNOSTIC_TEST
Intervention: ONSD
Description: ultrasound measurement of the optic nerve sheath diameter
Study: NCT04711304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Intraarticular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intraarticular injection
Study: NCT06106308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV Infusion
Study: NCT05916963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
Study: NCT05935618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-ING program ( Activity-based skill- and strength training to improve ingestion)
Description: The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
Study: NCT06464536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression
Description: conventional surgical gloves that are commonly used in hospitals will be used for compression therapy of both hands

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Compression
Description: conventional surgical gloves that are commonly used in hospitals will be used for compression therapy of both hands
Study: NCT06106308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion
Study: NCT06334601

Intervention type: DIAGNOSTIC_TEST
Intervention: Tests of upper airway collapsibility and muscle responsiveness.
Description: Upper airway collapsibility, upper airway muscle responsiveness and loop gain will be assessed during single study visit.~Polysomnography
Study: NCT06327204

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 940-nm diode laser / one session
Description: laser therapy using a 940-nm diode laser / one session per week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 940-nm diode laser / two session
Description: laser therapy using a 940-nm diode laser / two session per week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 940-nm diode laser/ three session
Description: laser therapy using a 940-nm diode laser / three session per week